Lifecore receives Nasdaq delisting notice for missing annual meeting and filing delays

LIFECORE BIOMEDICAL, INC. DE

Nasdaq notified Lifecore on June 3, 2024 of non-compliance with listing rules.
Failure to hold 2023 annual meeting within 12 months of fiscal year-end (May 28, 2023) triggered Rule 5620(a).
Delays in filing Q1, Q2, and Q3 FY2024 Forms 10-Q violate Rules 5810(c)(2)(G) and 5250(c)(1).
Company has scheduled 2023 annual meeting for August 15, 2024 and will request extension from Nasdaq Hearings Panel.
Nasdaq previously granted stay; delisting decision is pending; no immediate effect on stock trading.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.